Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
O14519

UPID:
CDKA1_HUMAN

ALTERNATIVE NAMES:
Deleted in oral cancer 1; Putative oral cancer suppressor

ALTERNATIVE UPACC:
O14519; F5GYA4

BACKGROUND:
The protein Cyclin-dependent kinase 2-associated protein 1, with alternative names Deleted in oral cancer 1 and Putative oral cancer suppressor, inhibits CDK2 and is part of the NuRD complex affecting chromatin structure. This activity is vital for controlling cell division and maintaining genomic integrity.

THERAPEUTIC SIGNIFICANCE:
Exploring Cyclin-dependent kinase 2-associated protein 1's function offers a promising avenue for developing new treatments. Given its critical role in regulating cell growth and gene expression, targeting this protein could lead to innovative therapies for diseases characterized by abnormal cell proliferation, such as cancer.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.